Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab

BACKGROUND: Nivolumab is an anti-PD1 checkpoint inhibitor active in patients with advanced melanoma and as adjuvant therapy in high-risk metastatic melanoma patients. METHODS: In this single-center retrospective analysis, we investigated the CD73 enzyme activity in patients with metastatic melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Morello, Silvana, Capone, Mariaelena, Sorrentino, Claudia, Giannarelli, Diana, Madonna, Gabriele, Mallardo, Domenico, Grimaldi, Antonio M., Pinto, Aldo, Ascierto, Paolo Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716054/
https://www.ncbi.nlm.nih.gov/pubmed/29202855
http://dx.doi.org/10.1186/s12967-017-1348-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716054/
https://www.ncbi.nlm.nih.gov/pubmed/29202855
http://dx.doi.org/10.1186/s12967-017-1348-8

Ejemplares similares